Does levodopa accelerate the pathologic process in Parkinson disease brain?
نویسندگان
چکیده
منابع مشابه
Does levodopa accelerate the pathologic process in Parkinson disease brain?
BACKGROUND Several in vitro studies have suggested levodopa (L-dopa) to be toxic to dopaminergic neurons and that it can modulate the aggregation process of α-synuclein. We investigated the relationship between cumulative lifetime dose of l-dopa and nigral neuronal count and Lewy body (LB) pathology in Parkinson disease (PD). METHODS Density of pigmented neurons was measured unilaterally in a...
متن کاملWhere does parkinson disease pathology begin in the brain?
The substantia nigra is not the induction site in the brain of the neurodegenerative process underlying Parkinson disease (PD). Instead, the results of this semi-quantitative study of 30 autopsy cases with incidental Lewy body pathology indicate that PD in the brain commences with the formation of the very first immunoreactive Lewy neurites and Lewy bodies in non-catecholaminergic neurons of th...
متن کاملThe acute brain response to levodopa heralds dyskinesias in Parkinson disease
OBJECTIVE In Parkinson disease (PD), long-term treatment with the dopamine precursor levodopa gradually induces involuntary "dyskinesia" movements. The neural mechanisms underlying the emergence of levodopa-induced dyskinesias in vivo are still poorly understood. Here, we applied functional magnetic resonance imaging (fMRI) to map the emergence of peak-of-dose dyskinesias in patients with PD. ...
متن کاملParadoxical worsening of gait with levodopa in Parkinson disease.
Neurology 2012;78:446–447 Despite many recent advances in the treatment of Parkinson disease (PD), levodopa is still the most effective medication for PD. While there are many “nondopaminergic” features of PD that do not improve with levodopa, PD motor symptoms generally improve with dopaminergic medications. However, not all the motor manifestations of PD are improved to the same extent and so...
متن کاملOptimizing extended-release carbidopa/levodopa in Parkinson disease
Purpose of review: To help clinicians optimize the conversion of a patient’s Parkinson disease pharmacotherapy from immediate-release carbidopa/levodopa (IR CD/LD) to an extended-release formulation (ER CD/ LD). Recent findings: Eleven movement disorders specialists achieved consensus positions on the modification of trial-based conversion guidelines to suit individual patients in clinical prac...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology
سال: 2011
ISSN: 0028-3878,1526-632X
DOI: 10.1212/wnl.0b013e318232ab4c